Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

On behalf of my coauthors, I thank Dr Hersey for his insightful analysis of our manuscript describing pyrexia characteristics in patients treated with dabrafenib plus trametinib, a topic of critical importance given that pyrexia is the most common adverse event associated with this treatment combination. The goal of our manuscript was to describe pyrexia incidence and management patterns among patients who received dabrafenib plus trametinib in clinical trials. Notably, the 1076 patients included in our analysis encompassed those with advanced non-small cell lung cancer (n  = 82), stage III resectable melanoma (n = 435), or unresectable/metastatic melanoma (n = 559) [1].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Author ’s reply Source Type: research